Needham initiated coverage of ICU Medical with a rating of Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $165.00 | Hold → Buy | Needham |
| 8/15/2025 | $145.00 | Overweight | Piper Sandler |
| 3/12/2025 | $205.00 → $197.00 | Outperform → Strong Buy | Raymond James |
| 12/11/2024 | $200.00 | Hold → Buy | Jefferies |
| 10/14/2024 | $183.00 | Hold | Jefferies |
| 6/21/2024 | Hold | Needham | |
| 6/17/2024 | $135.00 | Mkt Perform → Outperform | Raymond James |
| 11/8/2022 | Outperform → Mkt Perform | Raymond James |
Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2026. First Quarter 2026 Results The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. First quarter 2026 GAAP revenue declined 12% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 1%. First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior yea
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2026 earnings release and conference call. The Company will release its first quarter 2026 results on Thursday, May 7, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 7, 2026. The call can be accessed at 1-800-343-4136, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websit
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 Company management will present at the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Monday, March 2, 2026. The presentation will begin at 11:15 a.m. PT (2:15 p.m. ET). KeyBanc Healthcare Forum on March 18, 2026 Company management will participate in a fireside chat at the KeyBanc Healthcare Forum, held virtually on Wednesday, March 18,
SD - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Needham upgraded ICU Medical from Hold to Buy and set a new price target of $165.00
Piper Sandler initiated coverage of ICU Medical with a rating of Overweight and set a new price target of $145.00
Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously
SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2026. First Quarter 2026 Results The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. First quarter 2026 GAAP revenue declined 12% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 1%. First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior yea
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2026 earnings release and conference call. The Company will release its first quarter 2026 results on Thursday, May 7, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 7, 2026. The call can be accessed at 1-800-343-4136, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websit
SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2025 was $203.0 million, as compared to $227.3 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2025 was 38%, as compared to 36% in the same period in the prior year. GAAP net loss for the fourth quarter of 2025
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)